Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 201–300 of 1,000
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment
Hanks, B. A., Holtzhausen, A., Evans, K. S., Jamieson, R., Gimpel, P., Campbell, O. M., Hector-Greene, M., Sun, L., Tewari, A., George, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65745 · Cited by 120
“Many of these mechanisms create an immunotolerant microenvironment and suppress the generation of an effective antitumor immune response, allowing tumors to ultimately escape cancer immunosurveillance (3, 4).”
Critical roles of Bcl11b in T‐cell development and maintenance of T‐cell identity
Liu, P., Li, P., & Burke, S. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00953.x · Cited by 120
“In particular, there have been intensive efforts made by many groups in the area of cellular therapy to not only identify how best to harness the immune response for use against tumors but also why most immunotherapy fails to control tumors (103, 104).”
BackgroundBerezhnoy, A., Stewart, C. A., McNamara, J. O., Thiel, W. H., Giangrande, P. H., Trinchieri, G., & Gilboa, E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.18 · Cited by 120
Shibuya, K. C., Goel, V. K., Xiong, W., Sham, J. G., Pollack, S. M., Leahy, A. M., Whiting, S. H., Yeh, M. M., Yee, C., Riddell, S. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096565 · Cited by 119
Immunogenicity of anthracyclines: moving towards more personalized medicine
Apétoh, L., Mignot, G., Panaretakis, T., Kroemer, G., & Zitvogel, L. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.002 · Cited by 137
The immunogenicity of tumor cell death
Kepp, O., Tesnière, A., Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831bc375 · Cited by 130
Li, T., Yi, S., Liu, W., Jia, C., Wang, G., Hua, X., Tai, Y., Zhang, Q., & Chen, G. (2013) · Medical Oncology · doi:10.1007/s12032-013-0663-z · Cited by 121
Birkholz, K., Hombach, A. A., Krug, C., Reuter, S., Kershaw, M. H., Kämpgen, E., Schuler, G., Abken, H., Schaft, N., & Dörrie, J. (2009) · Gene Therapy · doi:10.1038/gt.2008.189 · Cited by 116
Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer?
Panzarini, E., Inguscio, V., & Dini, L. (2013) · BioMed Research International · doi:10.1155/2013/482160 · Cited by 114
“, hyaluronan, heparin sulphate, and degraded matrix constituents) [59], and signals/structures not yet fully characterized, for example, tumor cell-derived exosomes [60, 61].”
BackgroundThe Role of Regulatory T Cells in Cancer
Ha, T.-Y. (2009) · Immune Network · doi:10.4110/in.2009.9.6.209 · Cited by 131
“outgrowth of poorly immunogenic tumor -cell variant (immunoselection, a process that is also known as immunoediting) and through immunosubversion (1,2) The immune system interacts with tumors throughout their development, and the consequences of this interaction have substantial implications for cancer therapy.”
BackgroundBakdash, G., Buschow, S. I., Gorris, M. A. J., Halilovic, A., Hato, S. V., Sköld, A. E., Schreibelt, G., Sittig, S. P., Torensma, R., Duiveman-de Boer, T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1695 · Cited by 115
“They have been suggested to disrupt chemokine circuits that are pivotal for T-cell attraction (34, 35), can manipulate vascular endothelium to form a physical barrier in the face of tumor-reactive T cells (36), and can actively suppress these cells (37).”
BackgroundThe complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 124
Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses
Nakamura, M., Bodily, J. M., Beglin, M., Kyo, S., Inoue, M., & Laimins, L. A. (2009) · Virology · doi:10.1016/j.virol.2009.02.036 · Cited by 114
“HPV gene products can induce many of the cellular changes characteristic of the tumor phenotype (Hanahan andWeinberg, 2000; Zitvogel et al., 2006), including independence from growth control signals (Suprynowicz et al.”
Bos, J. D., & Luiten, R. M. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-78574-5_5 · Cited by 118
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
de Kruijf, E. M., van Nes, J. G. H., Sajet, A., Tummers, Q. R. J. G., Putter, H., Osanto, S., Speetjens, F. M., Smit, V. T. H. B. M., Liefers, G. J., van de Velde, C. J. H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1844 · Cited by 112
“Clin Cancer Res; 16(4) February 15, 2010 1275”
BackgroundInfluentialNeurobiology of Cancer: The Role of β-Adrenergic Receptor Signaling in Various Tumor Environments
Mravec, B., Horváthová, Ľ., & Hunáková, Ľ. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217958 · Cited by 123
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 135
“Chemotherapeutic agents also increase the immunogenicity of tumors by exposing MHC molecules and antigens on the surface of tumor cells [37].”
BackgroundThe Immune System — is it Relevant to Cancer Development, Progression and Treatment?
Prestwich, R. J. D., Errington‐Mais, F., Hatfield, P., Merrick, A. E., Ilett, E. J., Selby, P. J., & Melcher, A. A. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.10.011 · Cited by 136
Monteiro, A. C., Leal, A. C., Gonçalves-Silva, T., Mercadante, A. C. T., Kestelman, F., Chaves, S. B., Azevedo, R. B., Monteiro, J. P., & Bonomo, A. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068171 · Cited by 122
“To escape, a tumor cell must modify its intrinsic and extrinsic factors [5,6], favoring its own growth.”
Harnessing γδ T cells in anticancer immunotherapy
Hannani, D., Ma, Y., Yamazaki, T., Déchanet‐Merville, J., Kroemer, G., & Zitvogel, L. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.006 · Cited by 129
Annese, V., Ďuricová, D., Gower‐Rousseau, C., Jess, T., & Langholz, E. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv190 · Cited by 111
New views on natural killer cell-based immunotherapy for melanoma treatment
Burke, S., Lakshmikanth, T., Colucci, F., & Carbone, E. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.003 · Cited by 124
Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
Garg, A. D., Dudek, A. M., & Agostinis, P. (2013) · BioFactors · doi:10.1002/biof.1125 · Cited by 108
“In this scenario, the immune system starts acting as a selection force that actively eliminates the “residual” highly immunogenic cancer cells while exhibiting inability in controlling the “clonal expansion” of the low immunogenic cancer cells [2,3,5].”
BackgroundInfluentialDC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma
Maes, W., Galicia, G., Verbinnen, B., Boon, L., Vleeschouwer, S. D., Ceuppens, J. L., & Gool, S. V. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-004 · Cited by 116
Sayour, E. J., Grippin, A., Leon, G. D., Stover, B. D., Rahman, M., Karachi, A., Wummer, B. M., Moore, G. L., Castillo‐Caro, P., Fredenburg, K. M., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02179 · Cited by 111
He, W., Hao, J., Dong, S., Gao, Y., Tao, J., Chi, H., Flavell, R. A., O’Brien, R. L., Born, W. K., Craft, J. E., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903767 · Cited by 117
“They can recognize tumor-associated Ags directly, even when the function of traditional Ag-presenting dentritic cells is impaired or suppressed in tumor microenvironment (3, 36).”
Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response
Bénéteau, M., Zunino, B., Jacquin, M. A., Meynet, O., Chiche, J., Pradelli, L. A., Marchetti, S., Cornille, A., Carles, M., & Ricci, J.-E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206360109 · Cited by 106
“Evidence from in vivo experiments indicates that some anticancer agents favor the induction of immunogenic cancer cell death leading to tumorspecific immune responses, a mechanism described as contributing to the eradication of chemotherapy-resistant cancer cells and cancer stem cells (7, 8).”
BackgroundHuman and mouse PD-L1: similar molecular structure, but different druggability profiles
Magiera‐Mularz, K., Kocik-Krol, J., Musielak, B., Plewka, J., Sala, D., Machula, M., Grudnik, P., Hajduk, M., Czepiel, M., Siedlar, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101960 · Cited by 114
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S.-H., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 103
Host–tumor interactions in nasopharyngeal carcinomas
Gourzonès, C., Barjon, C., & Busson, P. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.002 · Cited by 115
Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
Prado-García, H., Romero‐Garcia, S., Aguilar‐Cázares, D., Meneses-Flores, M., & López-González, J. S. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/741741 · Cited by 133
“This theory involves three phases: elimination, equilibrium, and escape [12, 13].”
BackgroundOncosuppressive Functions of Autophagy
Morselli, E., Galluzzi, L., Kepp, O., Mariño, G., Michaud, M., Vitale, I., Maiuri, M. C., & Kroemer, G. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3478 · Cited by 104
“…pathogen resistance, production of type I interferon, antigen presentation, tolerance and lymphocyte development, negative regulation of cytokine signaling) (238), it is tempting to speculate that autophagy might function as an antitumor mechanism by (indirectly) favoring immunosurveillance (266).”
T-cell death and cancer immune tolerance
Lu, B., & Finn, O. J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402274 · Cited by 119
“Avoidance of immunosurveillance is proposed to be the seventh hallmark of cancer.(14,15) This happens through many well-characterized mechanisms including induction of T-cell tolerance by autochthonous tumors,(16) cancer immunoediting,(17) and development of an immune suppressive cancer microenvironment.”
BackgroundBloy, N., Garcia, P., Laumont, C. M., Pitt, J. M., Sistigu, A., Stoll, G., Yamazaki, T., Bonneil, E., Buqué, A., Humeau, J., et al. (2017) · Immunological Reviews · doi:10.1111/imr.12582 · Cited by 103
NK Cell Phenotypic Modulation in Lung Cancer Environment
Jin, S., Deng, Y., Hao, J.-W., Li, Y., Liu, B., Yu, Y., Shi, F.-D., & Zhou, Q.-H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109976 · Cited by 101
“Previous literature implied that some molecules expressing in the tumor and some mediums released from tumor commonly led to tumor escape mechanisms from NK cell immunological surveillance [19,20].”
BackgroundThe New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression
Benito-Martin, A., Di Giannatale, A., Ceder, S., & Peinado, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00066 · Cited by 100
Dudek-Perić, A. M., Ferreira, G. B., Muchowicz, A., Wouters, J., Prada, N., Martin, S., Kiviluoto, S., Winiarska, M., Boon, L., Mathieu, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2089 · Cited by 99
“Evidence indicates that anticancer therapies capable of harnessing the host's immune system while inducing cancer cell death hold the highest therapeutic value (1, 2).”
BackgroundBedel, R., Thiery-Vuillemin, A., Grandclément, C., Balland, J., Rémy-Martin, J.-P., Kantelip, B. M., Pallandre, J., Pivot, X. B., Ferrand, C., Tiberghien, P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-09-4540 · Cited by 113
“The immune system can detect and suppress emerging tumors (1).”
Baltz, K. M., Krusch, M., Bringmann, A., Brossart, P., Mayer, F., Kloss, M., Baessler, T., Kumbier, I., Peterfi, A., Kupka, S., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7724com · Cited by 99
“Therefore, reduction of EpCAM expression due to constitutive GITRL signaling or under selective pressure by GITRexpressing immune cells might enable the tumor cells to spread and hide in niches where they might escape the immune response (33).”
BackgroundTumor Microenvironment and Immune Escape
Ferrone, S., & Whiteside, T. L. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.08.004 · Cited by 105
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies
Atreya, I., & Neurath, M. F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.561 · Cited by 98
Schildkopf, P., Ott, O. J., Frey, B., Wadepohl, M., Sauer, R., Fietkau, R., & Gaipl, U. S. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791959774 · Cited by 106
IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin
He, D., Li, H., Yusuf, N., Elmets, C. A., Athar, M., Katiyar, S. K., & Xu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032126 · Cited by 96
“Defects in immune surveillance are associated with tumor progression [1,2,3].”
BackgroundBaritaki, S., Katsman, A., Chatterjee, D., Yeung, K. C., Spandidos, D. A., & Bonavida, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5441 · Cited by 99
“Immune surveillance results primary by apoptosis of neoplastic cells induced by host effector cells such as NK and NKT cells, CTL, or IFN-producing killer dendritic cells via TRAIL, FasL, or perforin/granzyme-dependent mechanisms (1, 57).”
BackgroundRetractedImmune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
Adachi, K., & Tamada, K. (2015) · Cancer Science · doi:10.1111/cas.12695 · Cited by 103
Biomarkers in precision therapy in colorectal cancer
Reimers, M. S., Zeestraten, E. C. M., Kuppen, P. J. K., Liefers, G., & van de Velde, C. J. �. (2013) · Gastroenterology report · doi:10.1093/gastro/got022 · Cited by 106
“Furthermore, immune reactivity can become suppressed by the attraction of immunosuppressive regulatory T cells (Tregs) into the tumor microenvironment [113, 114].”
BackgroundTherapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 107
“However, tumor cells can escape immune surveillance either by a selection of non-immunogenic tumor cell variants (immunoselection) or by actively suppressing immune response (immunesubversion)[2].”
Kandalaft, L. E., Motz, G. T., Busch, J. I., & Coukos, G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_95 · Cited by 102
“The vascular endothelial barrier, frequently prohibitive to tumor-reactive T cells, is maintained by locally expressed cytokines, growth factors, and the nature and quantity of adhesion molecules expressed by the endothelium (Zitvogel et al. 2006).”
BackgroundDetchokul, S., Williams, E. D., Parker, M. W., & Frauman, A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12260 · Cited by 115
“Cancer immunosurveillance suggests that the immune system can detect and destroy precursors of cancer cells to stop progression to cancer (Zitvogel et al., 2006).”
BackgroundThe Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/430394 · Cited by 103
“sase (IDO), arginase-1, prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF), and cyclooxygenase-2 (COX-2) are examples of such molecules that can impede the proliferation and function of CD4+ and CD8+ T cells [5, 12, 16].”
BackgroundMyD88 and its divergent toll in carcinogenesis
Salcedo, R., Cataisson, C., Hasan, U., Yuspa, S. H., & Trinchieri, G. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.03.008 · Cited by 94
Urdinguio, R. G., Fernández, A. F., Moncada-Pazos, Á., Huidobro, C., Rodríguez, R. M. A., Ferrero, C., Martínez‐Camblor, P., Obaya, Á. J., Bernal, T., Parra‐Blanco, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0806 · Cited by 99
“which plays an important role in the defense against cancer (1, 2).”
BackgroundNLRC5/CITA: A Key Player in Cancer Immune Surveillance
Yoshihama, S., Vijayan, S., Sidiq, T., & Kobayashi, K. S. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.12.003 · Cited by 94
IL-27 in tumor immunity and immunotherapy
Murugaiyan, G., & Saha, B. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.002 · Cited by 99
Immune cell quantitation in normal breast tissue lobules with and without lobulitis
Degnim, A. C., Brahmbhatt, R. D., Radisky, D. C., Hoskin, T. L., Stallings‐Mann, M. L., Laudenschlager, M., Mansfield, A. S., Frost, M. H., Murphy, L., Knutson, K. L., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2896-8 · Cited by 108
“An even more intriguing possibility is that the mucosal immune system in the breast may serve a critical role in tumor immunosurveillance, supported by the previously established role for both CD8 T cells and dendritic cells in this process [42].”
BackgroundDastmalchi, N., Feizi, M. A. H., Khojasteh, S. M. B., Baradaran, B., & Safaralizadeh, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118239 · Cited by 95
Regulatory T Cells in Radiotherapeutic Responses
Schaue, D., Xie, M. W., Ratikan, J. A., & McBride, W. H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00090 · Cited by 103
“Multiple mechanisms have been described by which this is achieved (Zitvogel et al., 2006; Whiteside, 2009).”
BackgroundNatural immunity to pluripotency antigen OCT4 in humans
Dhodapkar, K. M., Feldman, D. R., Matthews, P., Radfar, S., Pickering, R., Turkula, S., Zebroski, H. A., & Dhodapkar, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915086107 · Cited by 97
“However, none of these nor similar studies evaluated the immunogenicity of ES-restricted antigens in humans or mice, which may provide a potential mechanism for immune-mediated surveillance (22) against unrestrained growth of pluripotent cells, as well as GCT.”
ResultTumor-associated autoantibodies as diagnostic and prognostic biomarkers
Heo, C.-K., Bahk, Y. Y., & Cho, E. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.12.236 · Cited by 104
“An increased number of MSCs then act upon tumor specific T-cells, inhibiting the T-cell responses through nitric–oxide (NO) synthesis (14), which may tip the balance in favor of a”
BackgroundSingle-cell immunology: Past, present, and future
Ginhoux, F., Yalin, A., Dutertre, C., & Amit, I. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.006 · Cited by 108
Thudium, K. B., Selby, M., Zorn, J. A., Rak, G. D., Wang, X.-T., Bunch, R. T., Hogan, J. M., Strop, P., & Korman, A. J. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0057 · Cited by 95
“An effective immune response against cancer relies on immune surveillance of tumor antigens expressed on cancer cells, which ultimately results in an adaptive immune response and cancer cell death (2-4).”
BackgroundMazet, J. M., Mahale, J. N., Tong, O., Watson, R. A., Lechuga‐Vieco, A. V., Pirgova, G., Lau, V. W. C., Attar, M., Koneva, L. A., Sansom, S. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35948-9 · Cited by 110
Immune infiltrates as predictive markers of survival in pancreatic cancer patients
Protti, M. P., & De Monte, L. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00210 · Cited by 91
“MINI REVIEW ARTICLE published: 09 August 2013 doi: 10.3389/fphys.2013.00210 Immune infiltrates as predictive markers of survival in pancreatic cancer patients”
BackgroundInfluentialTumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
Park, H. J., Kusnadi, A., Lee, E.-J., Kim, W. W., Cho, B. C., Lee, I. J., Seong, J., & Ha, S.-J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.001 · Cited by 90
Human Cancer and Platelet Interaction, a Potential Therapeutic Target
Wang, S., Li, Z., & Xu, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041246 · Cited by 94
“MHC class I is usually downregulated in tumor cells [93].”
BackgroundGkountidi, A. O., Garnier, L., Dubrot, J., Angelillo, J., Harlé, G., Brighouse, D., Wrobel, L. J., Pick, R., Scheiermann, C., Swartz, M. A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0784 · Cited by 100
“The tumormicroenvironment (TME), which is amajor regulator of cancer development, is generally a highly immunosuppressive milieu (1, 2).”
BackgroundFrom cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 107
Opportunities for immunotherapy in microsatellite instable colorectal cancer
Westdorp, H., Fennemann, F. L., Weren, R. D. A., Bisseling, T. M., Ligtenberg, M. J. L., Figdor, C. G., Schreibelt, G., Hoogerbrugge, N., Wimmers, F., & de Vries, I. J. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1832-7 · Cited by 96
“Moreover, secretion of interleukin-10 and TGFβ at the tumor site was shown to act immunosuppressively (as reviewed in [89–91]).”
BackgroundLohneis, P., Sinn, M., Bischoff, S., Jühling, A., Pelzer, U., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Oettle, H., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.016 · Cited by 95
“Over the past decades it has been recognised that the complex tumour microenvironment with its multiple different cell types like cancer-associated fibroblasts, endothelial cells, pericytes and different immune cells has an important impact on the development [1] and behaviour of different solid tumours.”
Tumor stress, cell death and the ensuing immune response
Ullrich, E., Bonmort, M., Mignot, G., Kroemer, G., & Zitvogel, L. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402266 · Cited by 103
“In addition, tumor-induced tolerance might be considered as the seventh hallmark of tumorigenesis.(11) What are then the possible strategies to reverse or counterbalance tumorinduced immune tolerance? Here, we will discuss that some”
BackgroundInterleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells
O’Sullivan, T., Saddawi-Konefka, R., Gross, E., Tran, M., Mayfield, S. P., Ikeda, H., & Bui, J. D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.073 · Cited by 88
“The failure of the adaptive immune response to control antigenic tumors can involve multiple mechanisms that are intrinsic to the tumor cell, including antigen loss and acquisition of inhibitory ligands, or tumor-cell-extrinsic effects, including immune suppressive cytokines and antigen tolerance (Schreiber et al., 20…”
BackgroundPrerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 91
“THE PERCEPTION OF IMMUNOGENIC CELL DEATH BY THE IMMUNE SYSTEM Oncogenesis is a multistep mechanism that also involves an escape from immunosurveillance; that is, often cancer cells that sustain tumor growth are poorly immunogenic (immunoselection) and/or they actively inhibit immune functions (immunosubversion).(40) I…”
BackgroundThe role of the Major Histocompatibility Complex in the spread of contagious cancers
Belov, K. (2011) · Mammalian Genome · doi:10.1007/s00335-010-9294-2 · Cited by 51
“By modulating the expression of classical and nonclassical MHC Class I molecules, cells have evolved strategies to evade immune detection (Algarra et al. 2000, 2004; Bubenik 2004; Cabrera et al. 2003; Ferrone and Marincola 1995; Garcia-Lora et al. 2003; Ugurel et al. 2002; Zitvogel et al. 2006).”
BackgroundThe role of immunonutritional support in cancer treatment: Current evidence
Prieto, I., Montemuiño, S., Luna, J., de Torres, M. V., & Amaya, E. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.11.015 · Cited by 96
A Review of Mathematical Models of Cancer–Immune Interactions in the Context of Tumor Dormancy
Wilkie, K. P. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-1445-2_10 · Cited by 92
“[41] for a review) suggests that immunosurveillance has a significant role in cancer development and in anticancer therapy.”
BackgroundKinseth, M. A., Jia, Z., Rahmatpanah, F. B., Sawyers, A., Sutton, M., Wang‐Rodriguez, J., Mercola, D., & McGuire, K. L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28326 · Cited by 85
“An inflammatory, stromal microenvironment surrounds the tumor and allows cancerous cells to escape these regulatory controls.(13,32,33) We have found many genes associated with the stability of cell adhesion sites and stress fiber formation via integrin signaling differentially expressed in CA prostate samples when co…”
BackgroundResultReimers, M. S., Engels, C. C., Putter, H., Morreau, H., Liefers, G. J., van de Velde, C. J., & Kuppen, P. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-486 · Cited by 87
“Third, immune reactivity can become suppressed by the attraction of immunosuppressive regulatory T cells (Tregs) into the tumor microenvironment [17,18].”
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
Jure‐Kunkel, M., Masters, G. R., Girit, E., Dito, G., Lee, F. Y., Hunt, J. T., & Humphrey, R. W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1451-5 · Cited by 93
“Furthermore, during cancer progression, tumor cells can develop multiple strategies to evade immune detection and destruction [1, 2]; thus, agents that modulate immune function are attractive therapeutic options to generate and expand robust and effective antitumor immune responses.”
BackgroundIto, S.-E. A., Shirota, H., Kasahara, Y., Saijo, K., & Ishioka, C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2043-6 · Cited by 92
Redmond, W. L., Gough, M. J., Charbonneau, B., Ratliff, T. L., & Weinberg, A. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7244 · Cited by 95
“Tumors induce immunosuppression through a variety of mechanisms (17, 18) and the tumor microenvironment is therefore unlikely to provide a sufficient proinflammatory milieu to promote extensive endogenous OX40L expression on APCs (36–38).”
BackgroundLiu, K., Zhao, K., Wang, L., & Sun, E. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.05.010 · Cited by 88
Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?
Beaugerie, L. (2011) · Gut · doi:10.1136/gutjnl-2011-301133 · Cited by 90
Challenges and prospects of immunotherapy as cancer treatment
Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 100
Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1894 · Cited by 84
“The acquisition of immune evasion mechanisms, however, allows cancer cells to grow and metastasize despite of the presence of a measurable antitumor immune response (27, 28).”
BackgroundImmune checkpoint modulation: Rational design of combination strategies
Zamarin, D., & Postow, M. A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.003 · Cited by 90
Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk
Atashgaran, V., Wrin, J., Barry, S. C., Dasari, P., & Ingman, W. V. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00267 · Cited by 97
“Studies on breast tumor microenvironment demonstrate that Tregs, macrophages, and other immune cells have critical roles in the immune evasion abilities of the tumor in the breast (49).”
BackgroundA Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development
Shi, D., & Jiang, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762651 · Cited by 92
The resolution of inflammation and cancer
Rodríguez‐Vita, J., & Lawrence, T. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.006 · Cited by 100
“barrier to cancer [3].”
Immunoregulatory activity of adenosine and its role in human cancer progression
Muller-Haegele, S., Müller, L., & Whiteside, T. L. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.915739 · Cited by 85
“Zitvogel and colleagues have described interactions between the immune system and the developing tumor in terms of a series of successive steps, starting with immune surveillance, followed by tumor immune selection and culminating in tumor immune escape [36].”
BackgroundImmunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81
“This ‘‘natural selection’’ of less immunogenic tumor cells over time has been coined ‘‘tumor immunoediting’’ and is mainly supported in animal models [7,8].”
Neurotransmitters as Regulators of Tumor Angiogenesis and Immunity: The Role of Catecholamines
Sarkar, C., Chakroborty, D., & Basu, S. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9395-7 · Cited by 95
“…elicits or escapes an immune response within the host body is a very interesting aspect of tumor progression owing to the fact that tumors originate from transformation of normal cells and the immune system fails to recognize these cells as non self (Zitvogel et al. 2006; Schreiber et al. 2011).”
BackgroundKim, B., Yi, E. H., & Ye, S. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0795-8 · Cited by 87
“These inflammatory cells are diverse in size and composition among tumors, and the presence of these cells is believed to be evidence that the host is not ignorant of the developing tumor, but instead attempts to suppress tumor progression (Galon et al. 2006; Zitvogel et al. 2006).”
Bertucci, F., Finetti, P., Simeone, I., Hendrickx, W., Wang, E., Marincola, F. M., Viens, P., Mamessier, É., Ceccarelli, M., Birnbaum, D., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0309-1 · Cited by 89
Wu, X., Feng, Q., Wang, Y., Shi, J., Ge, H., & Di, W. J. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0749-9 · Cited by 90
Isidori, A., Salvestrini, V., Ciciarello, M., Loscocco, F., Visani, G., Parisi, S., Lecciso, M., Očadlíková, D., Rossi, L., Gabucci, E., et al. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.958464 · Cited by 88
“The main reason for these results relies on the fact that in cancer patients, the efficacy of vaccineinduced, tumor-specific T cells is significantly hampered by the presence of tumor-induced suppressor pathways [85], whose disruption may profoundly impact the capacity of vaccines to effectively induce and expand tumo…”
BackgroundHalama, N., Michel, S., Kloor, M., Zoernig, I., Pommerencke, T., Doeberitz, M. V. K., Schirmacher, P., Weitz, J., Grabe, N., & Jäger, D. (2009) · PubMed · Cited by 93
Toohey, K. L., Pumpa, K. L., McKune, A. J., Cooke, J., Welvaert, M., Northey, J. M., Quinlan, C., & Semple, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07295-1 · Cited by 99
In-situ tumor vaccination: Bringing the fight to the tumor
Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J., & Kohrt, H. E. K. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1049779 · Cited by 82
“Tumors & Th1/cell-mediated immunity Tumors deploy multiple parallel mechanisms to inhibit the generation of anti-tumor immune responses.(19,20) Anti-cancer immune responses appear largely to capitalize on immune mechanisms, which evolved to enable the detection and clearance of intracellular microbial pathogens like v…”
BackgroundMalignancies in Inflammatory Bowel Disease
Greuter, T., Vavricka, S. R., König, A. O., Beaugerie, L., Scharl, M. M., & on behalf of Swiss IBDnet, A. O. W. G. O. T. S. S. O. G. (2020) · Digestion · doi:10.1159/000509544 · Cited by 85
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.